Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
Jing Xu, Tanya E. Keenan, Beth Overmoyer, Nadine Tung, Rebecca Gelman, Karleen Habin, Judy E. Garber, Leif W. Ellisen, Eric P. Winer, Paul E. Goss, Beow Y. Yeap, Bruce A. Chabner, Steven J. Isakoff
Topics & Concepts
VeliparibMedicineInternal medicineMetastatic breast cancerBreast cancerCohortTolerabilityOncologyClinical endpointPARP inhibitorCancerClinical trialAdverse effectPoly ADP ribose polymeraseBiochemistryGeneChemistryPolymerasePARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies